IN2012DN03271A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03271A
IN2012DN03271A IN3271DEN2012A IN2012DN03271A IN 2012DN03271 A IN2012DN03271 A IN 2012DN03271A IN 3271DEN2012 A IN3271DEN2012 A IN 3271DEN2012A IN 2012DN03271 A IN2012DN03271 A IN 2012DN03271A
Authority
IN
India
Prior art keywords
pharmaceutical compositions
methods
pioglitazone
diabetes
inhibitor
Prior art date
Application number
Inventor
Nicholas Birringer
Christopher T John
Zhen Liu
Adam Procopio
Bhagwant Rege
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2012DN03271A publication Critical patent/IN2012DN03271A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
IN3271DEN2012 2009-10-23 2010-10-12 IN2012DN03271A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25429909P 2009-10-23 2009-10-23
PCT/US2010/052225 WO2011049773A1 (en) 2009-10-23 2010-10-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone

Publications (1)

Publication Number Publication Date
IN2012DN03271A true IN2012DN03271A (en) 2015-10-23

Family

ID=43900618

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3271DEN2012 IN2012DN03271A (en) 2009-10-23 2010-10-12

Country Status (12)

Country Link
US (1) US20120201885A1 (en)
EP (1) EP2490534A4 (en)
JP (1) JP2013508370A (en)
KR (1) KR20120104523A (en)
CN (1) CN102573476A (en)
AU (1) AU2010308433A1 (en)
BR (1) BR112012009496A2 (en)
CA (1) CA2777231A1 (en)
IN (1) IN2012DN03271A (en)
MX (1) MX2012004673A (en)
RU (1) RU2012121185A (en)
WO (1) WO2011049773A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086675A1 (en) * 2011-06-14 2014-01-15 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF INHIBITORS OF DIPEPTIDIL PEPTIDASA-4 WITH SIMVASTATIN
US20140248345A1 (en) * 2011-10-24 2014-09-04 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin
JP6313343B2 (en) * 2013-03-06 2018-04-18 ノバルティス アーゲー Formulation of organic compounds
EP3038465B1 (en) * 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
TR201402685A1 (en) * 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations of vildagliptin
CN105030724A (en) * 2015-08-20 2015-11-11 杭州成邦医药科技有限公司 Composition of anti-diabetic drugs
CN108096227A (en) * 2018-01-25 2018-06-01 河北科技大学 The molten film preparation in Egelieting oral cavity
JP7109748B2 (en) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 Solid preparation containing azilsartan and amlodipine besilate and method for producing solid preparation
WO2022074664A1 (en) * 2020-10-05 2022-04-14 V-Ensure Pharma Technologies Private Limited An immediate release composition of sitagliptin hydrochloride
CN115227661B (en) * 2022-09-22 2022-12-13 北京惠之衡生物科技有限公司 Linagliptin tablet and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US20090253752A1 (en) * 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CN101208085B (en) * 2005-06-10 2011-01-05 诺瓦提斯公司 Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
AR071175A1 (en) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO

Also Published As

Publication number Publication date
EP2490534A1 (en) 2012-08-29
CA2777231A1 (en) 2011-04-28
US20120201885A1 (en) 2012-08-09
AU2010308433A1 (en) 2012-06-07
RU2012121185A (en) 2013-11-27
EP2490534A4 (en) 2013-06-12
BR112012009496A2 (en) 2015-09-29
JP2013508370A (en) 2013-03-07
CN102573476A (en) 2012-07-11
WO2011049773A1 (en) 2011-04-28
MX2012004673A (en) 2012-06-14
KR20120104523A (en) 2012-09-21

Similar Documents

Publication Publication Date Title
IN2012DN03271A (en)
IL212485A0 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009155001A3 (en) Wnt protein signalling inhibitors
EP2473047A4 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2480082A4 (en) Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP1986652A4 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1978804A4 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2019677A4 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MY160456A (en) Benzodiazepine bromodomain inhibitor
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
WO2009089494A3 (en) Pharmaceutical compositions
IN2012DN02805A (en)
UA114710C2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PL2247602T3 (en) Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
MX370429B (en) Pharmaceutical compositions comprising bi-1356 and metformin.
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP2538783A4 (en) Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2009068214A3 (en) Heteroaryl-substituted piperidines
WO2009111239A3 (en) Pyrrolidine derivatives
MY149028A (en) Nalmefene hydrochloride dihydrate
ZA200807488B (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
MX2009012920A (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome.
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
IL208463A (en) 2-heterocyclyl-fused pyrrole compounds, pharmaceutical compositions comprising them and their use in the prophylaxis or treatment of diabetes or obesity